[Results of the combined treatment of advanced multiple myeloma by the M-2 protocol: cyclophosphamide, vincristine, melphalan, nitrosourea and prednisone].
Gola
A
A
Niewolna
M
M
Weryńska
B
B
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone
Wyniki złozonego leczenia późnego okresu szpiczaka plazmocytowego według programu M-2: cyklofosfamidem, winkrystyna, melfalanem, nitrozomocznikiem i prednisonem.